Reata Pharmaceuticals (RETA) announced that interim data from an extension Phase 2 clinical trial, LARIAT, evaluating its lead product candidate bardoxolone methyl (bard) in pulmonary arterial hypertension (PAH), showed a sustained treatment effect. Specifically, the increase in six-minute walk distance (6MWD) demonstrated by bard-treated patients at week 16 was "not significantly different" through 32 weeks. In addition, bard-treated patients with connective tissue disease-associated PAH showed similar sustained results through week 32. The company plans to submit the data for presentation at a future medical conference. A Phase 3 study, CATALYST, is set to commence shortly.